Skip to main content
Premium Trial:

Request an Annual Quote

Florian Heupel, David Mahoney, Peter Bell, Richard de Silva, Mason Morfit

Florian Heupel has become CEO of MWG-Biotech, a member of the Eurofins Scientific group. He joined Eurofins Scientific as group marketing director in Brussels in 2002. In addition, he has served as CEO of GeneScan Europe, another Eurofins business, since 2004. Heupel holds a PhD in organic chemistry from the University of Oxford and an undergraduate degree in chemistry from the University of Bonn in Germany.

David Mahoney has become director of global intellectual property and US legal affairs for Febit, the company said last week, a new position. He will be based on Febit’s US offices. Previously, he was US director of legal affairs for Sygnis Pharma.

Peter Bell and Richard de Silva have been promoted to general partners at Highland Capital Partners, the company said last week. Highland Capital Partners is an investor of Helicos BioSciences.

Mason Morfit has joined Advanced Medical Optics’ board of directors, the company said last week. He is a partner at San Francisco-based ValueAct Capital Partners and a former director of Solexa. Morfit holds a bachelor's degree from Princeton University.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.